risankizumab
M16-066
Phase 3 small_molecule active
Quick answer
risankizumab for Ulcerative Colitis (UC) is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Ulcerative Colitis (UC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active